-+ 0.00%
-+ 0.00%
-+ 0.00%

Xenetic Biosciences agrees to acquire Santersus in all-stock share exchange deal

PUBT·09/16/2026 11:02:11
Listen to the news
Xenetic Biosciences agrees to acquire Santersus in all-stock share exchange deal
  • Xenetic Biosciences will acquire privately held Santersus in an all-stock share exchange, subject to shareholder approval.
  • The combined company is expected to remain Nasdaq-listed as Santersus Bio under ticker SNTS.
  • Deal combines Santersus’ NucleoCapture blood purification platform with Xenetic’s DNase technology, both aimed at neutrophil extracellular traps.
  • Pipeline includes pivotal-stage sepsis and systemic lupus erythematosus programs, each holding FDA Breakthrough Device Designation.
  • Leadership is expected to shift to Santersus CEO James Ladtkow, with Xenetic interim CEO and CFO James Parslow continuing in management.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609160700ACCESSWRNAPR_____1221382) on September 16, 2026, and is solely responsible for the information contained therein.